Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Mansfield CA, Johnson FR, Van Houtven GL. The missing piece: valuing averting behavior for children's ozone exposures. Resour Energy Econ. 2006 Aug;28(3):215-28.
Smith VK, Poulos C, Kim H. Treating open space as an urban amenity. Resour Energy Econ. 2002 Feb 15;24(1-2):107-29.
Wagner JD, Carlson CS, O'Brien TD, Anthony MS, Bullock BC, Cefalu WT. Diabetes mellitus and islet amyloidosis in cynomolgus monkeys. J Am Assoc Lab Anim. 1996 Feb;48(1):36-41.
Miller EW, Anthony MS, Lusso FM, McLaughlin KJ. Nonhuman primate colony census projection and management. J Am Assoc Lab Anim. 1982;32:423.
Kaplan JR, Anthony MS, Wood L. Domestic breeding of patas monkeys (Erythrocebus patas). J Am Assoc Lab Anim. 1981 Aug;31(4):409-12.